Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

Table 1 Baseline characteristics of the study population, in median (IQR)

Variable	Units	Median	25th Pctl	75th Pctl	n
BMI	kg/m²	30.2	27.9	34.1	39
Age	years	64.0	58.0	68.0	39
Weight	kg	93.0	85.0	108.0	39
HbA1c^a	mmol/mol	47 (6)			39
Fasting glucose	mmol/l	5.3	5.0	6.2	39
Fasting glucagon^a	pmol/l	5.3 (3.5)
Fasting C-peptide	pmol/l	1474	1006	1978	39
Fasting insulin	pmol/l	110	67	178	38
Fasting NEFA	mmol/l	0.392	0.298	0.455	39
AUC_glucose	mmol/l × ¹²⁰min	821.3	750.5	915.5	39
AUC_insulin	pmol/l × ¹²⁰min	33,173	25,350	45,625	38
AUC_ISR	pmol/kg	969.5	811.1	1263.6	38
AUC_NEFA	mmol/l × ¹²⁰min	28.9	22.5	36.1	39
HOMA-IR		4.43	2.24	6.93	38
ISI_Composite	l²/mg/microU	3.2	2.03	4.62	38
B-total		2.54	1.61	3.2	38
MCRi_kg	l/kg/min	0.029	0.023	0.036	37
MCRi_total	l/min	2.548	2.219	3.164	37
DI		8.06	5.71	12.91	37
IDR_basal	pmol/kg/min	3.09	1.94	4.02	37
HEXi		0.30	0.22	0.36	37
Pre-study ADT^b	n (%)
Diet and lifestyle intervention	24 (62)
Metformin	15 (38)
Sulfonylurea	1 (3)

ISSN: 1758-5996